In Management of Recurrent Miscarriage, Threatened Abortion & Luteal Phase Support in ART
A highly selective oral progestogen, DGEST® contains Dydrogesterone 10 mg per tablet and offers targeted support to maintain pregnancy and regulate the menstrual cycle. Manufactured by Health Care Pharmaceuticals, DGEST® restores progesterone’s crucial role in endometrial receptivity, reduces the risk of early pregnancy loss, and provides luteal‐phase support for assisted reproductive techniques.

Pharmacodynamics & Mechanism of Action

• Selective Progesterone Receptor Agonist: Dydrogesterone binds to uterine progesterone receptors, mimicking endogenous progesterone without androgenic or estrogenic effects.

• Endometrial Stabilization: Promotes secretory transformation of the endometrium, facilitating implantation and placental development.

• Immune Modulation: Helps maintain the maternal–fetal interface by down‐regulating inflammatory mediators.

Clinical Indications

1. Luteal Phase Support (LPS) in ART/IVF
    • From oocyte retrieval onward to confirm pregnancy

2. Threatened Abortion
    • Prevention of miscarriage in early gestation

3. Recurrent Pregnancy Loss (RPL) / Habitual Abortion
    • Maintenance therapy through the first two trimesters

Dosage & Administration

Tip: Administer with food to enhance gastrointestinal tolerance and maintain steady plasma levels.

Key Benefits of DGEST®

• Robust Pregnancy Maintenance: Significantly lowers risk of miscarriage in high-risk women

• Enhanced Implantation Rates: Improves outcomes in IVF and ICSI cycles

• Excellent Tolerability: Minimal side effects compared to earlier progestogens

• Simple Regimen: Oral dosing avoids injectable progestin discomfort